Impact of Tumour Hypoxia on Evofosfamide Sensitivity in Head and Neck Squamous Cell Carcinoma Patient-Derived Xenograft Models

Impact of Tumour Hypoxia on Evofosfamide Sensitivity in Head and Neck Squamous Cell Carcinoma Patient-Derived Xenograft Models

Tumour hypoxia is a marker of poor prognosis and failure of chemoradiotherapy in head and neck squamous cell carcinoma (HNSCC), providing a strategy for therapeutic intervention in this setting. To evaluate the utility of the hypoxia-activated prodrug evofosfamide (TH-302) in HNSCC, we established t...

Full description

Bibliographic Details
Main Authors: Julia K. Harms, Tet-Woo Lee, Tao Wang, Amy Lai, Dennis Kee, John M. Chaplin, Nick P. McIvor, Francis W. Hunter, Andrew M. J. Macann, William R. Wilson, Stephen M.F. Jamieson
Format: Article
Language:English
Published: MDPI AG 2019-07-01
Series:Cells
Subjects:
tumour hypoxia
head and neck squamous cell carcinoma (HNSCC)
evofosfamide
patient-derived xenograft (PDX)
pimonidazole
POR
MKI67
SLFN11
Online Access:https://www.mdpi.com/2073-4409/8/7/717

Internet

https://www.mdpi.com/2073-4409/8/7/717

Similar Items